PDCD1 and T-cell non-Hodgkin lymphoma: As previously cited, it is apparent that the use of anti-PD-1 ICIs in T-cell lymphomas is associated with a risk of hyperprogression, and in some subtypes, such as ATLL, their use is contraindicated.